Recent developments include positive clinical trial data for CELZ-201 in chronic lower back pain, expansion of the ADAPT trial after FDA clearance, advancement of AI-driven Project PHOENIX, capital raised through warrant exercises, and patent-related stock price gains.

• Creative Medical Technology's ADAPT trial for chronic lower back pain showed functional and pain improvements with positive interim data reported in January 2026 [N6][N7].
• The company completed enrollment for the ADAPT trial in December 2025 [N8].
• In June 2026, the company expanded the ADAPT trial following new FDA clearance [N4].
• Project PHOENIX, a nationwide AI-driven data collection initiative, advanced in June 2026 [N5].
• The company secured $4.5 million through warrant exercises as of July 1, 2026 [N2].
• Patent news in August 2026 contributed to a stock price increase [N1].
• A mid-year update in July 2026 noted a stock price decline [N3].

The company has advanced clinical programs with positive interim data in its ADAPT trial for chronic lower back pain and has expanded FDA clearance for dosing. Its proprietary platforms and AI-driven initiatives support diversified therapeutic development. Capital raised through warrant exercises strengthens liquidity. The company's focus on regenerative medicine across multiple indications broadens market opportunity and potential for future partnerships or commercialization.

Creative Medical Technology operates in a highly competitive and rapidly evolving biotechnology sector with limited operating history and minimal revenues. The company has reported consistent net losses and relies on capital raises to fund operations. Clinical and regulatory risks inherent in drug development remain significant. The company has limited marketing and sales capabilities and may face challenges in scaling commercial activities. Technological obsolescence and market acceptance risks also present challenges.

Creative Medical Technology's moat lies in its proprietary stem cell platforms (AlloStem, ImmCelz, iPScelz) and its FDA Fast Track designated lead clinical asset CELZ-201 for chronic lower back pain. The company has developed a scalable cGMP manufacturing process and holds intellectual property including patents related to erectile dysfunction and regenerative therapies. Its integration of AI in drug development and a network of strategic partners support efficient clinical advancement. However, the biotechnology sector's rapid technological changes and competitive landscape pose ongoing challenges to maintaining differentiation.

• Clinical and Regulatory Risk: The company’s lead assets are in early clinical stages with inherent risks of trial failure, regulatory delays, or non-approval which could materially impact operations.
• Financial Risk: The company has reported net losses and relies on external financing, including warrant exercises, to fund operations, which may dilute shareholders and affect financial stability.
• Market and Competitive Risk: Operating in a rapidly evolving biotech sector, the company faces competition from larger firms with greater resources and risks of technological obsolescence.
• Operational Risk: Limited marketing and sales experience and capabilities may delay or hinder commercialization efforts.

• Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company focused on regenerative therapeutics in immunotherapy, endocrinology, urology, neurology, and orthopedics [S2].
• The company operates through subsidiaries including Creative Medical Technologies, Inc., ImmCelz, Inc., StemSpine, Inc., and AlloCelz LLC, with ImmCelz and AlloCelz not yet commercial [S2].
• Its lead clinical asset is CELZ-201 (Olastrocel), an FDA Fast Track designated therapy for chronic lower back pain due to degenerative disc disease, currently in a randomized Phase 1/2 ADAPT trial [S2].
• CELZ-201 is also being developed for Type 1 diabetes in a Phase 1/2 CREATE 1 trial [S2].
• The company has three proprietary cell platforms: AlloStem (off-the-shelf donor derived perinatal tissue technology), ImmCelz (personalized immunotherapy reprogramming patient's own immune cells), and iPScelz (induced pluripotent stem cell platform) [S2].
• The company integrates AI into drug development activities to analyze biological and clinical data, prioritize targets, and enhance development efficiency [S2].
• Revenue is generated from the sale of disposable stem cell concentration kits, recognized upon delivery to customers; revenues are minimal and were zero for the six months ended June 30, 2026 [S2].
• Research and development expenses for the six months ended June 30, 2026 were $1,000,858, including costs related to two Phase I/II clinical trials and development of the ImmCelz, AlloStem, and iPScelz platforms [S2].
• Selling, general and administrative expenses for the six months ended June 30, 2026 were $1,968,685 [S2].
• The company reported a net loss of $1,511,976 for the three months ended June 30, 2026, and a net loss of $2,914,967 for the six months ended June 30, 2026 [S2].
• Basic and diluted earnings per share were negative $0.41 for the quarter ended June 30, 2026 [S2].
• As of June 30, 2026, the company had cash and cash equivalents of approximately $4.5 million and current assets of about $9.0 million, with current liabilities of approximately $0.7 million, resulting in a strong current ratio of 12.91 and cash ratio of 6.45 [S2].
• The company had 6,592,557 shares outstanding as of August 7, 2026 [S2].
• Management includes Timothy Warbington as CEO and Donald Dickerson as CFO, both with extensive experience in biotechnology and finance [S1].
• The company has ongoing clinical trials with positive interim data reported for the ADAPT trial in chronic lower back pain showing functional and pain improvements [N6][N7].
• The ADAPT trial enrollment for chronic lower back pain was completed as of December 18, 2025 [N8].
• The company expanded the ADAPT trial after receiving new FDA clearance in June 2026 [N4].
• Creative Medical advanced Project PHOENIX, a nationwide AI-driven data collection initiative, in June 2026 [N5].
• The company secured $4.5 million through warrant exercises as of July 1, 2026 [N2].
• Patent news in August 2026 contributed to a stock price increase [N1].
• The company issued a mid-year update in July 2026 noting stock price decline [N3].